A Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of the Investigational Product Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
Latest Information Update: 24 Feb 2026
At a glance
- Drugs Myelo 001 (Primary)
- Indications Influenza virus infections; Respiratory tract infections; Viral infections
- Focus Therapeutic Use
- Sponsors Valenta Pharmaceuticals
Most Recent Events
- 24 Feb 2026 New trial record